Concord Clinical And Translational Resource Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 19-12-2024
- Paid Up Capital ₹ 0.10 M
as on 19-12-2024
- Company Age 7 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue 190.00%
(FY 2020)
- Profit 72.65%
(FY 2020)
- Ebitda 77.55%
(FY 2020)
- Net Worth -72.34%
(FY 2020)
- Total Assets -42.23%
(FY 2020)
About Concord Clinical And Translational Resource
The Company is engaged in the Printing & Publishing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chandrashekar Basappa and Nagarajan Sukumar serve as directors at the Company.
- CIN/LLPIN
U22300KA2017PTC105572
- Company No.
105572
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Aug 2017
- Date of AGM
30 Dec 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Concord Clinical And Translational Resource?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandrashekar Basappa  | Additional Director | 28-Nov-2023 | Current |
| Nagarajan Sukumar | Additional Director | 04-Dec-2023 | Current |
Financial Performance of Concord Clinical And Translational Resource.
Concord Clinical And Translational Resource Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 190% increase. The company also saw a substantial improvement in profitability, with a 72.65% increase in profit. The company's net worth observed a substantial decline by a decrease of 72.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Concord Clinical And Translational Resource?
Unlock access to Concord Clinical And Translational Resource's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Concord Clinical And Translational Resource?
Unlock and access historical data on people associated with Concord Clinical And Translational Resource, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Concord Clinical And Translational Resource, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Concord Clinical And Translational Resource's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
